New trial
Phase 1/2 Patritumab Deruxtecan, HER3-directed Topoisomerase I Inhibitor ADC
- Trial ID
- NCT06941272 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- Exploratory
- Location
- 2 Locations
- Published in
- New in Oncology - July 3, 2025
The study evaluates safety, PK, and efficacy of patritumab deruxtecan as monotherapy in children with relapsed or refractory hepatoblastoma or rhabdomyosarcoma, given via IV every 3 weeks. The trial, conducted by Merck Sharp & Dohme in Iowa City and Seoul, explores a novel HER3-directed antibody-drug conjugate in pediatric oncology.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings